Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-EB-PSMA in mCRPC
NCT04996602Phase 1Unknown
- Sponsor
- Peking Union Medical College Hospital
- Start
- Jan 2019
- Primary completion
- Sep 2022
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 177Lu-PSMA-EB-01 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Peking Union Medical College Hospital. Primary endpoints: Prostate Specific Antigen Response at 1 month and 68Ga-PSMA PET/CT Response at 2 months. Status: unknown.
02
Drugs
177Lu-PSMA-EB-01
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT04996602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04996602.